Eastern Cooperative Oncology Group
ecog-acrin.orgLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
178
Active
12
Phase 3
41
Total enrollment
41,930
Pipeline matrix
Showing 16 of 16 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Temozolomide | — | — | — | — | 2 | ||
| High Dose Chemotherapy | — | — | — | — | — | 1 | |
| Stem Cell Mobilization Therapy | — | — | — | — | — | 1 | |
| Bortezomib | — | — | — | — | — | 2 | |
| cyclophosphamide | — | — | — | — | 19 | ||
| cytarabine | — | — | — | — | 8 | ||
| dexamethasone | — | — | — | — | 5 | ||
| Daratumumab-hyaluronidase | — | — | — | — | — | 1 | |
| Sulforaphane | — | — | — | — | — | 1 | |
| Bendamustine | — | — | — | — | — | 1 | |
| lenalidomide | — | — | — | — | — | 1 | |
| Daratumumab / Hyaluronidase | — | — | — | — | — | 1 | |
| Venetoclax | — | — | — | — | — | 1 | |
| CPX-351 | — | — | — | — | — | 1 | |
| Azacitidine | — | — | — | — | — | 1 | |
| rituximab | — | — | — | 10 |
Next readouts
- 2023-02-25
- 2026-02
- 2026-12-31
- 2027-02-01
- 2027-06-30
- 2028-04-30
- 2029-02-01
Top conditions
- Lymphoma20
- Leukemia20
- Breast Cancer19
- Head and Neck Cancer16
- Lung Cancer16
- Prostate Cancer13
- Melanoma (Skin)11
- Colorectal Cancer11
Frequently asked questions about Eastern Cooperative Oncology Group
- How many clinical trials does Eastern Cooperative Oncology Group have on ClinicalTrials.gov?
- Eastern Cooperative Oncology Group is listed as the lead sponsor on 178 clinical trials in ClinicalTrials.gov, 12 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Eastern Cooperative Oncology Group's trials are in Phase 3?
- 41 of Eastern Cooperative Oncology Group's trials are in Phase 3, spread across 16 active drug programs.
- What therapeutic areas does Eastern Cooperative Oncology Group focus on?
- Eastern Cooperative Oncology Group's most-studied conditions on ClinicalTrials.gov are Lymphoma, Leukemia, Breast Cancer, Head and Neck Cancer, Lung Cancer.
- When are Eastern Cooperative Oncology Group's next clinical trial readouts?
- Eastern Cooperative Oncology Group has 7 upcoming primary-completion readouts tracked here; the soonest is “Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma”, expected around 2023-02-25.